“It feels good to play the vaccine produced by ourselves, especially the ‘made in Shanghai’ vaccine produced through such hard work.”
At about 4 p.m. on January 27, Zuo min, executive director and President of Shanghai Pharmaceuticals Holding Co.Ltd(601607) received a covid-19 vaccine at a covid-19 temporary vaccination site in Baoshan, Shanghai. The vaccine is a recombinant New Coronavirus vaccine (adenovirus type 5) developed by Cansino Biologics Inc(688185) biological and academician Chen Wei, and was approved in China in February 25, 2021.
Shanghai Pharmaceuticals Holding Co.Ltd(601607) executive director and President Zuo min injected covid-19 vaccine at a covid-19 temporary vaccination site in Baoshan, Shanghai
Covid-19 vaccine has been approved for some time. The special feature of Zuo min’s covid-19 vaccine lies in its place of origin – at 2 p.m. on January 27, covid-19 produced by Shanghai Baoshan factory of Shangyao Cansino Biologics Inc(688185) biopharmaceutical Co., Ltd. (hereinafter referred to as “Shangyao Cansino Biologics Inc(688185) ) was officially put on the market. Zuo min was the first batch of covid-19 vaccine made in Shanghai. This factory is also the first covid-19 vaccine production base in Shanghai.
The deeper connection between this vaccine and Zuo min is that Shanghai Pharmaceuticals Holding Co.Ltd(601607) (601607. Sh, 02607. HK) stands behind the application of Cansino Biologics Inc(688185) . In January 2021, Shanghai Pharmaceuticals Holding Co.Ltd(601607) signed a joint venture with Cansino Biologics Inc(688185) bio and Shanghai bio pharmaceutical industry equity investment fund, and set up drug Cansino Biologics Inc(688185) to carry out restructuring New Coronavirus vaccine production cooperation.
From the signing of the agreement to the formal mass production and listing of the vaccine, this “vaccine super factory” in Shanghai only took nearly a year to create a new “Shanghai speed”. For Shanghai Pharmaceuticals Holding Co.Ltd(601607) , the operation of this factory also marks that this century old enterprise has officially entered the hot vaccine field.
How was covid-19 vaccine super factory refined?
Since the covid-19 outbreak in early 2020, covid-19 vaccine has always been regarded as an important tool for global epidemic prevention and control. In China, many vaccine companies have invested in vaccine research and development, and five technical routes have been promoted at the same time. So far, seven vaccines have been approved, Cansino Biologics Inc(688185) adenovirus vector covid-19 vaccine, which is the only single shot covid-19 vaccine among the seven covid-19 vaccines approved for use in China, is one of them.
From scratch, it is not easy to make covid-19 vaccine with guaranteed safety and effectiveness. With covid-19 vaccine, how to ensure sufficient production capacity and make vaccine accessible to more people is another challenge that must be faced. Cansino Biologics Inc(688185) in addition to establishing a vaccine production line in its headquarters in Tianjin, bio has also found a partner – Shanghai Pharmaceuticals Holding Co.Ltd(601607) in Shanghai.
In February 2021, Shanghai Pharmaceuticals Holding Co.Ltd(601607) together with Cansino Biologics Inc(688185) biology and Shanghai biomedical industry equity investment fund jointly created a vaccine manufacturing entity – Shangyao Cansino Biologics Inc(688185) was officially established. Shanghai biomedical industry equity investment fund was officially launched in December 2020. This fund was initiated and operated by Shanghai Pharmaceuticals Holding Co.Ltd(601607) superior company Shangshi group.
Speed is important. From the official establishment of Shangyao Cansino Biologics Inc(688185) to the mass production and marketing of covid-19 vaccine made in Shanghai, it took less than a year.
Zuo min sighed at the listing ceremony: “although we have Shanghai Pharmaceuticals Holding Co.Ltd(601607) gone through a hundred years, vaccine manufacturing has told us that it is completely zero, so this project starts from zero, and this project is a result of full support and help from many parties from project initiation, site selection, construction, completion and operation to today’s product listing.”
In the process of preparation and construction, Shanghai Pharmaceuticals Holding Co.Ltd(601607) the main leaders of the group led the establishment of a major vaccine project team, started from scratch, started the construction of four production buildings, the decoration of one complex building and the transformation of supporting public engineering facilities, and quickly promoted the procurement, installation, commissioning and technical verification of facilities and equipment.
In one year, from the commencement of construction to the acquisition of production license, a “vaccine super factory” rose. It can be said that this is driven by “Shanghai strength” and “Shangyao responsibility”, realizing the “Shanghai speed” of “founded, completed and put into operation in the same year”.
Shangyao Cansino Biologics Inc(688185) vaccine factory, located in Luodong Road, Baoshan District, Shanghai, covers an area of 50 mu, with a construction area of about 50000 square meters and an annual production capacity of 200 million doses of covid-19 vaccine. It is also the first covid-19 vaccine production base in Shanghai.
On the afternoon of January 27, the surging reporter approached the vaccine production line of Cansino Biologics Inc(688185) and covid-19 vaccine products, which can only be seen at the vaccination point, operated on the track. From cleaning to capping, from light inspection to packaging, all links in all regions proceeded smoothly.
The reason why it is called “super factory” is not only the annual production capacity of 200 million doses, but also because it is a digital, intelligent and automatic vaccine factory. According to the staff, the workshop can not only make full use of the advanced technology of intelligent manufacturing, connect with the Internet through information sensing equipment such as radio frequency identification, realize the process automation and intelligent condition control in the vaccine production process, adopt online automatic cleaning and sterilization equipment, and realize online weighing through automatic filling production line, so as to realize less people operation in the core production area. At the same time, the detection efficiency and accuracy are improved through automatic light inspection, and the packaged finished products are automatically transported to the second floor warehouse at the fastest speed, so as to shorten the exposure time of products to normal temperature.
Moreover, in the whole process, each vaccine has a unique traceability code. Relying on the whole process information traceability system, you can see the origin and destination of the vaccine at a glance.
enter the field of vaccine production and make a new breakthrough in medicine in the past century
Since the covid-19 epidemic, innovative products represented by covid-19 vaccine have detonated the global vaccine market, and high valued vaccine enterprises such as biontech and Moderna have been rapidly born. In China, the reliance of Sinopharm, Kexing, Cansino Biologics Inc(688185) and others on covid-19 vaccine has also attracted public attention.
Vaccine is a special drug, not only because it is mainly used for disease prevention rather than treatment, but also because of its long production cycle, high technical content and strict regulatory requirements.
In terms of business, Shanghai Pharmaceuticals Holding Co.Ltd(601607) can be divided into two business segments: pharmaceutical industry and pharmaceutical commerce, which is in the lead in the field of vaccine import in China. According to the 2020 annual report data, in terms of imported vaccines, Shanghai Pharmaceuticals Holding Co.Ltd(601607) revenue exceeded 5.2 billion, with a year-on-year increase of more than 53%, making an important contribution to profit growth.
Its agent GlaxoSmithKline recombinant herpes zoster vaccine (Xin’an Lishi) achieved sales of nearly 500 million yuan in the whole year.
Since the covid-19 outbreak, Shanghai Pharmaceuticals Holding Co.Ltd(601607) began to deploy and start the strategic layout in the field of vaccine manufacturing. In addition to the production cooperation with Cansino Biologics Inc(688185) biology on adenovirus vector covid-19 vaccine, it also participated in Chengdu wesk biomedical Co., Ltd. as a leading investor and reached strategic cooperation on vaccine development, industrialization and distribution.
Shanghai Pharmaceuticals Holding Co.Ltd(601607) entering the vaccine field is obviously not to catch up with hot spots, but a thoughtful consideration. Zuo min told the surging news reporter that Shanghai Pharmaceuticals Holding Co.Ltd(601607) itself has the advantage of adenovirus vector drug production technology platform in tumor drugs. In addition, the production of vaccines is more stringent than that of general drugs. Shangyao has very rich experience in drug production management. After entering the new field of vaccines, with the help of partners, it can also quickly establish a system in terms of team, system and process.
” Shanghai Pharmaceuticals Holding Co.Ltd(601607) as a large pharmaceutical enterprise controlled by the state in Shanghai, we undertake the platform guarantee of providing medical protection materials for all medical institutions in Shanghai.” Zuo Min said that entering the field of vaccine manufacturing is Shanghai Pharmaceuticals Holding Co.Ltd(601607) a new contribution to covid-19 epidemic prevention and control.
In Zuo min’s view, the quantitative listing of vaccines today is an extremely important event for Shanghai Pharmaceuticals Holding Co.Ltd(601607) , and there is more in-depth work ahead. Through this project, Shanghai Pharmaceuticals Holding Co.Ltd(601607) has entered the previously blank vaccine manufacturing field, and this factory not only produces covid-19 vaccine, but also pays close attention to cultivating and developing new vaccine products, including tumor vaccine.
Zhu Tao, chief scientific officer of Cansino Biologics Inc(688185) biology, also said at the listing ceremony that Cansino Biologics Inc(688185) biology hopes to produce, develop and market more vaccines in Shanghai.
